Core F: Biomarker Core

摘要-核心F：生物标志物核心 生物标志物正在成为有效临床管理和试验协调的工具组成部分， 阿尔茨海默病和相关痴呆症（ADRD），并将需要实现精准医疗 诊断和治疗的方法。新增加的生物标志物核心（BC）的主要功能 密歇根州阿尔茨海默病研究中心（MADRC）将促进创新研究， 建立和新的血液生物标志物，并提供专业知识和获得生物标志物测定技术 密歇根大学、密歇根州立大学、韦恩州立大学以及 其他ADRC BC的总体目标是使用最先进的超灵敏ELISA和定量质量 光谱法（MS）方法用于测量血液中的生物标志物、识别和构建新型血液基 生物标志物测定，并将生物标志物与疾病的临床测量相结合。我们将利用MADRC 为实现这一目标，并促进与《联合国千年宣言》相一致的研究， MADRC的中心主题是识别、理解和调节β-淀粉样蛋白以外的许多因素， 到ADRD。MADRC纵向队列和其他正在进行的临床研究中的多样化患者人群 研究工作，加上开发新的生物标志物测定的能力，将大大提高 BC关注关于当前和新型生物标志物 目标提高诊断准确性，并跟踪疾病进展和可预测性随着时间的推移，在多个 患者人群，包括代表性不足的种族/族裔群体。BC将继续执行以下五项 目的：1）提供已建立的血液生物标志物的测量，2）开发和实施新的生物标志物 3）促进血液生物标志物与已建立的临床实践的整合，以促进转化 研究，4）向国家阿尔茨海默氏症协调中心提供血液生物标志物数据，5）教育 并培训卫生保健专业人员、科学家和学生使用生物标志物测定。BC的目标和 通过与MADRC临床核心、数据管理和统计部门密切合作， 核心，神经影像学核心，神经病理学核心和研究教育组件。通过这些努力， 不列颠哥伦比亚省将显著加强由军事和国防研究中心支持的研究， 在我们建立对诊断和预测效用的全面评估时， 基于血液的生物标志物图谱。我们还将与其他ADRC和调查人员进行交流，以帮助制定一个 不断发展的痴呆症评估和治疗的临床前景。

ABSTRACT – CORE F: BIOMARKER CORE Biomarkers are becoming instrumental components of effective clinical management and trial coordination for Alzheimer’s disease and related dementias (ADRD), and will be required to enable precision medicine approaches to diagnosis and treatment. The primary functions of the newly added Biomarker Core (BC) of the Michigan Alzheimer’s Disease Research Center (MADRC) will be to facilitate innovative research into established and novel blood biomarkers, and provide expertise and access to biomarker assay technologies for investigators at the University of Michigan, Michigan State University, Wayne State University, as well as other ADRCs. The overall goal of the BC is to use cutting-edge ultrasensitive ELISA and quantitative mass spectrometry (MS) approaches to measure biomarkers in blood, identify and build novel blood-based biomarker assays, and integrate biomarkers with clinical measures of disease. We will leverage MADRC resources from ongoing and future efforts to achieve this goal and promote studies that align with the MADRC’s central theme to identify, understand and modulate the many factors beyond β-amyloid contributing to ADRD. The diverse patient population in the MADRC’s longitudinal cohort and other ongoing clinical research efforts, coupled with the ability to develop novel biomarker assays, will significantly enhance the ability of the BC to focus on unique questions regarding the extent to which current and novel biomarker targets enhance diagnostic accuracy, and track disease progression and predictability over time in multiple patient populations, including underrepresented racial/ethnic groups. The BC will pursue the following five aims: 1) provide measurements of established blood biomarkers, 2) develop and implement novel biomarker assays, 3) facilitate integration of blood biomarkers with established clinical practices to advance translational research, 4) contribute blood biomarker data to the National Alzheimer’s Coordinating Center, and 5) educate and train health care professionals, scientists and students in the use of biomarker assays. The BC goals and aims will be achieved by working closely with the MADRC Clinical Core, Data Management and Statistical Core, Neuroimaging Core, Neuropathology Core, and Research Education Component. Through these efforts, the BC will markedly enhance research supported by the MADRC, leading to a sustained and significant impact for the field as we build a comprehensive assessment of the diagnostic and the predictive utility of blood-based biomarker profiles. We will also interface with other ADRCs and investigators to help shape an evolving clinical landscape for dementia evaluation and treatment.